MARKET

PIRS

PIRS

Pieris Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.080
+0.540
+15.25%
Opening 11:02 06/24 EDT
OPEN
3.710
PREV CLOSE
3.540
HIGH
4.190
LOW
3.700
VOLUME
11.66M
TURNOVER
--
52 WEEK HIGH
5.09
52 WEEK LOW
1.700
MARKET CAP
258.28M
P/E (TTM)
-5.9251
1D
5D
1M
3M
1Y
5Y
Pieris Pharmaceuticals shares rise after FDA orphan drug status for cinrebafusp
Pieris Pharmaceuticals shares rise ([[PIRS]] +8.5%) after the U.S. FDA granted orphan drug designation to cinrebafusp alfa (PRS-343) for the treatment of HER2-high and HER2-low expressing gastric cancers.FDA grants orphan
Seekingalpha · 1h ago
Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer
BOSTON, MA / ACCESSWIRE / June 24, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other ...
ACCESSWIRE · 3h ago
Pieris' Gastric Cancer Therapeutic Receives FDA Orphan Drug Designation; Shares Climb Pre-Bell
MT Newswires · 5h ago
21 Stocks Moving in Monday's Pre-Market Session
Gainers Raven Industries, Inc. (NASDAQ: RAVN) rose 47.2% to $56.86 in pre-market trading. CNH Industrial N.V
Benzinga · 3d ago
Shareholders May Be Wary Of Increasing Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package
Shareholders will probably not be too impressed with the underwhelming results at Pieris Pharmaceuticals, Inc...
Simply Wall St. · 5d ago
Thinking about buying stock in Pieris Pharmaceuticals, Midatech Pharma, ContextLogic, Barrick Gold, or Lordstown Motors?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, MTP, WISH, GOLD, and RIDE.
PR Newswire - PRF · 06/17 14:50
Pieris Pharma US Patent & Trademark Office Abstract Filed For Co.'s 'Proteins specific for calcitonin gene-related peptide'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5518&f=G&l=50&d=PTXT&p=111&S1=20210615&OS=20210615&RS=20210615
Benzinga · 06/15 17:17
Pieris Pharmaceuticals Granted U.S. Patent 'Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5517&f=G&l=50&d=PTXT&p=111&S1=20210615&OS=20210615&RS=20210615
Benzinga · 06/15 17:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PIRS. Analyze the recent business situations of Pieris Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PIRS stock price target is 7.50 with a high estimate of 9.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 37.20M
% Owned: 58.76%
Shares Outstanding: 63.30M
TypeInstitutionsShares
Increased
22
1.01M
New
6
169.09K
Decreased
28
2.18M
Sold Out
8
234.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.78%
Pharmaceuticals & Medical Research
+1.60%
Key Executives
Non-Executive Chairman/Independent Director
James Geraghty
Chairman/Independent Director
james Geraghty
President/Chief Executive Officer/Director
Stephen Yoder
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance/Treasurer
Thomas Bures
Senior Vice President/Chief Scientific Officer
Hitto Kaufmann
Independent Director
Ann Barbier
Independent Director
Peter Kiener
Independent Director
Christopher Kiritsy
Independent Director
Michael Richman
Independent Director
Maya Said
Independent Director
Matthew Sherman
No Data
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.